Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. - Wikidata - wikimedia - TriplyDB

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

http://www.wikidata.org/entity/Q33162197

about

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Safety and diagnostic accuracy of tumor biopsies in children with cancer.Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.Personalized oncology in interventional radiology.Biopsies: next-generation biospecimens for tailoring therapy.Peri-procedural use of anticoagulants in radiology: an evidence-based review.Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

P2860

Q26992272-59BBC2F2-C49E-44BD-9F50-4BAE0A70933A Q33415400-F2149E9B-5A71-4201-8E76-C9230916A86B Q33440778-AC7D3A57-DE5D-4754-B163-43AE25E4605B Q35202350-EC23137C-B880-453D-9895-66ECD925CC47 Q36064901-06931D9E-C517-4073-8E58-1520664D4C09 Q37092371-2F196DF0-CB2D-4BBE-9F55-34EC93C62289 Q38116896-1B6A1728-0326-46A0-8966-5C8B343DFEE8 Q39077699-3D0C3835-007B-4306-80BF-57B2184F3EA4 Q51796512-1051E9FD-64ED-457C-A452-96602278F3E9

P2860

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

http://www.wikidata.org/entity/Q33162197

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@ast

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@en

type

label

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@ast

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@en

prefLabel

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@ast

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@en

P1433

Q33162197-BC8AB201-A051-4D19-96D2-BE852EE425AD

P1476

Q33162197-1553F4D1-BE80-47D7-9EEB-202A577C6DA6

P2093

Q33162197-0BA59EB5-B612-4E61-B8A5-1BBD8EA5B9D1

Q33162197-25F8066D-2060-47BE-BB87-364E37686E37

Q33162197-317C9C4B-3AB8-4BE2-9BBC-A5190B5E7A17

Q33162197-33F50AE3-9828-44DB-9782-198D0B68E59B

Q33162197-39A23AFC-4111-467C-92D0-46F1E96C6318

Q33162197-AE5A5C47-501F-4E3B-94CE-FE83D5E6DC2B

Q33162197-F302D62D-E51B-4578-A161-6DB467CC06E5

Q33162197-F952704C-1333-48B7-8212-2A13F5720300

Q33162197-FDFDBCC4-C1F7-4EC1-A7AF-302AA7EBC2AE

P2860

Q33162197-07DB2AAC-8FE2-42DD-AC4B-DA66546983EA

Q33162197-15CFEDF9-6506-4FB2-AA99-83378931C4C8

Q33162197-2A9E1F3E-6483-4952-A8A4-1E4372DBE9B2

Q33162197-4FA2A77A-62BD-4151-8078-89B91AE379F7

Q33162197-57A27AF6-9410-45B9-84E6-8E8148073894

Q33162197-5EF41457-945A-412F-8A14-A80842E63762

Q33162197-698FF198-ED0E-4E38-9797-FDEE736C72A7

Q33162197-6CF02AC6-5B36-4D7E-B015-A930C02533C5

Q33162197-781A489B-0635-406A-97F8-DA127A507932

Q33162197-989A9867-B1CE-441C-9E7D-5C36AF93F8E6

P304

Q33162197-E77F70B4-165F-41FD-9787-A884D19FA4ED

P31

Q33162197-7FD006C1-6EB5-4256-B705-7EDDDCD7BAA7

P356

Q33162197-AE0153BF-930B-4978-BA0B-790668162D35

P407

Q33162197-F010286A-8E4F-4B21-A2F7-C9D4D9EB9B86

P433

Q33162197-ABB6E583-87D2-4A61-9578-C1C482AF29BD

P478

Q33162197-56F718A9-9BE2-4168-AB23-24E4FE4BE82A

P50

Q33162197-21C00F11-6B0D-4F3D-8322-59068A3B502C

Q33162197-698FFA5B-72D2-4A69-B8C4-72BD79F0870D

Q33162197-8317670F-F862-4AD3-86D3-57CDC5ED2E2F

P577

Q33162197-D03B7F1E-0273-4B14-A9A0-D07F81DD7C89

P5875

Q33162197-4E1D6956-6647-4661-B288-3FA04416C082

P698

Q33162197-EDF1EDEB-8DC6-4726-842A-B7642B2BDCF9

P932

Q33162197-67CEE218-D60D-4271-9BEE-6D6B62573BBC

P356

P1433

P1476

Feasibility and safety of sequ ...... e biopsies in clinical trials.

@en

P2093

Christina Annunziata

http://www.w3.org/2001/XMLSchema#string

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Jennifer Squires

http://www.w3.org/2001/XMLSchema#string

John L Hays

http://www.w3.org/2001/XMLSchema#string

Jung-min Lee

http://www.w3.org/2001/XMLSchema#string

Lori Minasian

http://www.w3.org/2001/XMLSchema#string

Minshu Yu

http://www.w3.org/2001/XMLSchema#string

Nicole Houston

http://www.w3.org/2001/XMLSchema#string

Nilofer Azad

http://www.w3.org/2001/XMLSchema#string

P2860

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

Trastuzumab--mechanism of action and use in clinical practice

Proteomics and biomarkers in clinical trials for drug development

Clinical trial designs for predictive marker validation in cancer treatment trials

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.

Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations

P304

1357-1364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27916

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Bradford J. Wood

Katherine R. Calvo

P577

2012-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234031719

http://www.w3.org/2001/XMLSchema#string

P698

23280317

http://www.w3.org/2001/XMLSchema#string

P932

3604070

http://www.w3.org/2001/XMLSchema#string